THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED
HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE,
PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN
PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN,
SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION.
THE INFORMATION CONTAINED WITHIN THIS
ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE
INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE
REGULATION (EU) 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
30
December 2024
VALIRX PLC
("ValiRx" or the
"Company")
Result of General
Meeting
Issue of Equity, Warrants and
Total Voting Rights
Director/PDMR
Shareholding
ValiRx plc (the "Company") (AIM:
VAL), announces that, further to the Conditional Fundraising &
Notice of General Meeting announcements on 9 December 2024 and 10
December 2024, at its General Meeting held earlier today, all
resolutions were duly passed. Details of the votes received in
respect of the resolutions will be available shortly on the
Company's website.
In aggregate the Company has issued
241,999,999 New Ordinary Shares and 241,999,999 Fundraise Warrants
over new ordinary shares.
The Fundraise Warrants are
exercisable for a period of three years from Admission and are
exercisable at a price of 1.3 pence per new ordinary
share.
Director/PDMR Shareholdings
Following completion of the
Fundraising, the shareholdings of the Directors and persons closely
associated with them who have participated in the Fundraising are
set out in the table below:
|
Name
|
Number of existing Ordinary
Shares
|
Percentage of existing issued
share capital
|
Number of New Ordinary
Shares
|
Number of Ordinary Shares on
Admission
|
Percentage of enlarged share
capital on Admission
|
Number of Fundraise
Warrants
|
|
Mark Eccleston
|
1,976,957
|
1.49%
|
20,769,2301
|
22,746,187
|
6.08%
|
20,769,230
|
|
Adrian de Courcey
|
871,036
|
0.66%
|
1,538,461
|
2,409,497
|
0.64%
|
1,538,461
|
|
Cathy Tralau-Stewart
|
66,666
|
0.05%
|
769,231
|
835,897
|
0.22%
|
769,231
|
|
Gerry Desler
|
195,334
|
0.15%
|
769,231
|
964,565
|
0.26%
|
769,231
|
|
Martin Gouldstone
|
0
|
0.00%
|
769,231
|
769,231
|
0.21%
|
769,231
|
|
Total
|
3,109,993
|
2.35%
|
24,615,384
|
27,725,377
|
7.41%
|
24,615,384
|
1of which,
9,846,145 New Ordinary Shares have been subscribed for by Mark
Eccleston directly, 5,538,470 New Ordinary Shares have been
subscribed for by OncoLytika Ltd (a company in which Mr. Eccleston
is interested) and 2,307,692 New Ordinary Shares have been
subscribed for by Mark Eccleston's partner. In addition, Mr
Eccleston subscribed for a further 3,076,923 New Ordinary Shares as
part of the Broker Offer
Issue of Equity
The Placing Shares, the Subscription
Shares and the Broker Offer Shares have been allotted, conditional
upon Admission, and application has been made to the London Stock
Exchange for, in aggregate, 241,999,999 Placing Shares,
Subscription Shares and Broker Offer Shares to be admitted to
trading on AIM. Admission is expected to occur at 8.00 a.m. on or
around 31 December 2024, with dealings in the Placing Shares, the
Subscription Shares and the Broker Offer Shares commencing at the
same time. The Placing Shares, the Subscription Shares and the
Broker Offer Shares will rank pari passu with all other issued
Shares.
Total Voting Rights
For the purpose of the Disclosure
Guidance and Transparency Rules, following Admission the enlarged
issued share capital of the Company will comprise 374,348,672
ordinary shares of 0.1 pence each. The Company does not hold any
shares in the treasury. The above figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company, under the Disclosure
Guidance and Transparency Rules.
Capitalised terms used in this
announcement have the meaning given to them in the Conditional
Fundraising announcement dated 9 December 2024, unless otherwise
defined in this announcement.
The Directors of the Company take
responsibility for this announcement.
For further
information, please contact:
|
Investor
questions on this announcement
We encourage all investors to share
questions
on this announcement via our investor
hub
|
https://valirx.com/link/vPn48e
|
|
ValiRx
plc
Dr Mark Eccleston, CEO
|
Tel: +44 (0)
2476 796496
www.valirx.com
Mark.Eccleston@valirx.com
|
|
Cairn
Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0)
20 7213 0880
|
|
Shard Capital
Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0)
20 7186 9000
|
|
V
Formation (Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
|
+44 (0) 115
787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
|
a) Mark Eccleston
|
|
b) OncoLytika Ltd
|
|
c) Annette Williams
|
|
d) Adrian De-Courcey
e) Cathy Tralau-Stewart
|
|
f) Gerry Desler
g) Martin Gouldstone
|
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
a) Director
b) A company which Mark Eccleston
has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
|
|
b.
|
Initial notification/
Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
ValiRx PLC
|
|
b.
|
LEI
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary Shares
ISIN: GB00BLH13C52
|
|
b.
|
Nature of the transaction
|
Purchase of shares as part of the
Fundraising
|
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
a) 0.65p
|
|
b) 0.65p
|
|
c) 0.65p
|
|
d) 0.65p
|
|
e) 0.65p
|
|
f) 0.65p
|
|
g) 0.65p
|
|
|
a) 12,923,068
|
|
b) 5,538,470
|
|
c) 2,307,692
|
|
d) 1,538,461
|
|
e) 769,231
|
|
f) 769,231
|
|
g) 769,231
|
|
|
|
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
N/A
|
|
e.
|
Date of the transaction
|
30/12/2024
|
|
f.
|
Place of the transaction
|
Outside a trading venue
|
|
|
|
|
|
|
|
|
|
|
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
|
a) Mark Eccleston
|
|
b) OncoLytika Ltd
|
|
c) Annette Williams
|
|
d) Adrian De-Courcey
e) Cathy Tralau-Stewart
|
|
f) Gerry Desler
g) Martin Gouldstone
|
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
a) Director
b) A company which Mark Eccleston
has an interest
c) PCA of Mark Eccleston
d) Director
e) Director
f) Director
g) Director
|
|
b.
|
Initial notification/
Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
ValiRx PLC
|
|
b.
|
LEI
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Warrants over Ordinary Shares with
an exercise price of 1.3 pence per share and exercisable for a
period of three years from Admission.
ISIN: GB00BLH13C52
|
|
b.
|
Nature of the transaction
|
Fundraise Warrants received as part
of the Fundraising
|
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
a) 1.3p
|
|
b) 1.3p
|
|
c) 1.3p
|
|
d) 1.3p
|
|
e) 1.3p
|
|
f) 1.3p
|
|
g) 1.3p
|
|
|
a) 12,923,068
|
|
b) 5,538,470
|
|
c) 2,307,692
|
|
d) 1,538,461
|
|
e) 769,231
|
|
f) 769,231
|
|
g) 769,231
|
|
|
|
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
N/A
|
|
e.
|
Date of the transaction
|
30/12/2024
|
|
f.
|
Place of the transaction
|
Outside a trading venue
|
|
|
|
|
|
|
|
|
|
|
Notes for
Editors
About
ValiRx
ValiRx is a life science company focused on
early-stage cancer therapeutics and women's health, accelerating
the translation of innovative science into impactful medicines to
improve patient lives.
ValiRx provides the scientific, financial, and
commercial framework for enabling rapid translation of innovative
science into clinical development.
Using its extensive and proven experience in
research and drug development, the team at ValiRx selects and
incubates promising novel drug candidates and guides them through
an optimised process of development, from pre-clinical studies to
clinic and investor-ready assets.
ValiRx connects diverse disciplines across
scientific, technical, and commercial domains, with the aim of
achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's portfolio are
outlicensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of the London
Stock Exchange in October 2006 and trades under the ticker symbol:
VAL.
For further information, visit:
www.valirx.com